Simple blood test could replace risky prenatal procedures for down syndrome
NCT ID NCT01118507
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new blood test that looks at fetal DNA in the mother's blood to detect Down syndrome (trisomy 21) as early as the first trimester. Researchers enrolled 976 pregnant women at high risk and compared the blood test results to standard invasive methods. The goal was to see if this noninvasive approach could accurately identify affected pregnancies, potentially offering a safer alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a safe, noninvasive way to detect Down syndrome early in pregnancy, reducing the need for risky invasive tests.
- What could go wrong
- The test is still being validated and may not be as accurate as traditional methods. It also requires further study before widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRISOMY 21 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chi Poissy St Germain
Poissy, 78300, France
-
Necker Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could replace risky amniocentesis for down syndrome diagnosis
- New nasal device could help kids with down syndrome sleep soundly
- New study maps normal heart function in newborns
- Father's age may matter in down syndrome screening, study suggests
- Massive biobank aims to unlock secrets of down syndrome